NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous MelanomaGlobeNewsWire · 1 day ago
Voting Rights and Shares Capital of the CompanyGlobeNewsWire · 5 days ago
Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?Defense World · Oct 3, 2026
Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Still a Buy?Defense World · Oct 2, 2026
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial OfficerGlobeNewsWire · Oct 1, 2026
NANOBIOTIX Provides First Half 2026 Operational and Financial UpdateGlobeNewsWire · Sep 24, 2026Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 29, 2026 | -$0.48 | -$0.80 | Miss |
| Mar 31, 2026 | $0.30 | -$0.46 | Miss |
| Sep 30, 2025 | -$0.25 | -$0.13 | Beat |
| Apr 2, 2025 | -$0.62 | -$1.01 | Miss |
| Nov 12, 2024 | -$0.51 | -$0.50 | Beat |
| Apr 24, 2024 | -$0.83 | -$0.33 | Beat |